Literature DB >> 22521781

World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution.

Ji-Hye Park1, Hyun-Tae Shin, Dong-Youn Lee, Joo-Heung Lee, Jun-Mo Yang, Kee-Taek Jang, Young-Hyeh Ko.   

Abstract

BACKGROUND: The relative frequency and the clinicopathological characteristics of lymphoma may vary according to geography and ethnicity. Data are limited regarding the features of cutaneous lymphoma (CL) presented according to the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC) classification (2005) in Korea.
OBJECTIVE: The study determined the relative frequency of CL in Korea and presented the clinical relevance of CL based on the WHO-EORTC classification.
METHODS: We reclassified the cases of CL collected over a 16-year period in a tertiary institution-based dermatologic setting in Korea.
RESULTS: In all, 164 cases were divided into 96 primary and 68 secondary CL. The group of primary CL consisted of T- and natural killer-cell lymphomas (84.3%), B-cell lymphomas (13.5%), and immature hematopoietic malignancies (2%). The Korean population presented with a higher rate of T-cell and natural killer-/T-cell CL and a lower rate of cutaneous B-cell lymphoma than Western countries. Compared with 2003 Korean data, the rate of mycosis fungoides was lower and the rate of nasal and nasal-type natural killer-/T-cell lymphomas was higher. LIMITATIONS: This study was retrospective and based on a single-center experience.
CONCLUSION: As the relative frequency of lymphomas differs widely with geography and ethnicity, there is a need to collect more data to describe the epidemiologic characteristics in the Far East.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22521781     DOI: 10.1016/j.jaad.2012.02.033

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Peripheral T cell lymphoma in Asia.

Authors:  Sanghui Park; Young Hyeh Ko
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

2.  Cardiac Involvement and Subsequent Death due to Extranodal NK/T Cell Cutaneous T-Cell Lymphoma: An Autopsy Case and Brief Review of the Literature.

Authors:  Nikolaos D Goutas; Emmanouil I Sakelliadis; Eleftheria Lakiotaki; Konstantinos D Katsos; Kalliroi Spanou; Pinelopi Korkolopoulou; Dimitrios G Vlachodimitropoulos
Journal:  Iran J Pathol       Date:  2020-06-12

3.  Transformation of primary cutaneous follicle centre lymphoma into primary cutaneous diffuse large B-cell lymphoma of other type.

Authors:  Ivan Z Petković; Ivica Pejčić; Danica Tiodorović; Miljan Krstić; Slavica Stojnev; Svetislav Vrbić
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

4.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

5.  Mycosis Fungoides and Variants of Mycosis Fungoides: A Retrospective Study of 93 Patients in a Chinese Population at a Single Center.

Authors:  Yixin Luo; Zhaorui Liu; Jie Liu; Yuehua Liu; Wei Zhang; Yan Zhang
Journal:  Ann Dermatol       Date:  2019-12-27       Impact factor: 1.444

6.  Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study.

Authors:  Chutipon Pruksaeakanan; Phurichaya Teyateeti; Poramin Patthamalai; Janista Thumrongtharadol; Manasmon Chairatchaneeboon
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

Review 7.  Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.

Authors:  Kwei-Lan Liu; Wen-Chien Tsai; Chih-Hung Lee
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.